RxPG News : Anti-Inflammatory

Cyclin-dependent kinase inhibitors: The latest anti-inflammatory

Mon, 04 Sep 2006 16:41:00 PST

People who suffer from inflammatory conditions such as chronic diseases of the lung, joints and other organs could benefit from a new discovery by scientists at the University of Edinburgh. A new study in Nature Medicine journal shows that certain drugs, already being tested as cancer treatments, can dramatically reduce tissue inflammation.

Ibuprofen - worsening cognitive function

Sat, 22 Jul 2006 05:22:00 PST

Researchers at the University of Pennsylvania School of Medicine found that chronic ibuprofen therapy given after brain injury worsens cognitive abilities. These findings in a preliminary, animal-model study have important implications for traumatic brain injury (TBI) patients who are often prescribed such nonsteroidal anti-inflammatory drugs (NSAIDS) as ibuprofen for chronic pain.

COX 2 inhibitors associated with increased risk of vascular events

Fri, 02 Jun 2006 22:55:00 PST

High doses of some traditional non-steroidal anti-inflammatory drugs (NSAIDS) are associated with similar cardiovascular risks as the new generation of anti-inflammatory drugs known as COX 2 inhibitors (like Vioxx ®), finds a study in this week's BMJ.

Therapeutic prospects beyond COX -2 inhibitors

Sat, 15 Apr 2006 08:42:00 PST

Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which COX -2 inhibitor drugs like Celebrex and Vioxx cause heart problems, in multiple animal models. The findings offer the prospect of a new generation of anti-inflammatory drugs that bypass this issue, as reported in the April 13 online edition and May print issue of The Journal of Clinical Investigation.

Ceramide Kinase (CERK) may be a target for new anti-inflammatory drugs

Sun, 04 Dec 2005 10:22:00 PST

Virginia Commonwealth University researchers studying the enzyme that triggers inflammation have found that it may be a target for a new class of anti-inflammatory drugs to treat arthritis, asthma, multiple sclerosis, lung and colon cancers and Alzheimers disease.

No evidence for greater stomach protection by Cox-2 Inhibitors

Fri, 02 Dec 2005 19:14:00 PST

There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in this weeks BMJ.

European Medicines Agency update on non-selective NSAIDs

Mon, 17 Oct 2005 19:05:00 PST

The Agencys scientific committee, the Committee for Medicinal Products for Human Use (CHMP), concluded, at its meeting of 10-13 October 2005, that, on the basis of the data reviewed, there are no new safety concerns regarding cardiovascular and gastrointestinal safety and serious skin reactions with non-selective NSAIDs (non-steroidal anti-inflammatory drugs). NSAIDs remain important treatments for arthritis and other painful conditions.

NSAIDS and Cox 2 inhibitors increase risk of MI - Study

Sun, 12 Jun 2005 20:48:00 PST

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Eszopiclone Cost Effective in Long-Term Treatment of Insomnia

Tue, 17 May 2005 19:26:00 PST

Sepracor Inc. (Nasdaq: SEPR - News) announces the presentation of results from two analyses designed to assess potential pharmacoeconomic benefits associated with the use of LUNESTA(TM) brand eszopiclone in the long-term treatment of insomnia.

FDA asks Pfizer to withdraw Bextra and add boxed warning to Celebrex

Fri, 08 Apr 2005 10:16:00 PST

The Food and Drug Administration ( FDA ) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription ( over-the-counter ( OTC ) ) non-selective NSAID medications.

COX 2 Inhibitors for Colorectal Adenoma Prevention Increase Serious Cardiovascular Events

Sat, 26 Mar 2005 14:48:00 PST

Researchers affiliated with the Adenoma Prevention with Celecoxib (APC) study have reported that Celebrex® (celecoxib) increased serious cardiovascular events. Similar conclusions were reached by the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial. Both studies were reported in the March 17, 2005 issue of the New England Journal of Medicine.

Research Shows that FDAs New Recommendations will Benefit COX-2 Inhibitors Though Physicians and Patients Remain Hesitant

Thu, 24 Mar 2005 09:48:00 PST

New FDA Advisory Committee Recommendations around COX-2s are likely to lead to prescribing gains for Bextra and Celebrex, though both physicians and patients will continue to shy away from Vioxx, even if it returns to market.New NOP World Health research shows that physicians, particularly general and family practitioners, anticipate increasing their Bextra prescribing, while internists, rheumatologists and orthopedic surgeons expect to boost their Celebrex prescribing.Patients taking Celebrex or Bextra are loyal to those products and plan to continue taking them.

Celecoxib Reduces Proliferation of Cancer Cells by also Targeting Cyclin D1

Sat, 19 Mar 2005 10:19:00 PST

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

In studies published in the March 1 issue of the journal Clinical Cancer Research, scientists at the Weill Medical College of Cornell University revealed that celecoxib, marketed under the name Celebrex, not only targets COX-2, but also reduces levels of a key protein, cyclin D1, thats critical for cell replication.

Prospective trial confirms Rofecoxib's cardiovascular risks

Wed, 16 Feb 2005 15:22:00 PST

The trial, known as APPROVe (Adenomatous Polyp Prevention on Vioxx), was the longest test yet of Vioxx as a chemoprevention agent, and was designed to determine whether the drug could prevent the re-growth of precancerous colon polyps in people who had already had polyps removed. The prospective chemoprevention study randomized 2,586 participants from 108 centers in 29 countries to receive either 25 mgs. of Vioxx daily or a placebo drug for three years, 2001-2004. The trial was stopped September 30, 2004 - approximately two months before its planned completion.